The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

Attilio Ignazio Lo Monte, Francesco Carini, Giovanni Tomasello, Marcello Romeo, Giuseppe Damiano, Antonella Marino Gammazza, Vincenzo Davide Palumbo, Salvatore Buscemi, Provvidenza Damiani, Attilio Ignazio Lo Monte, Abdo Jurjus, Francesco Carini, Antonella Marino Gammazza, Provvidenza Damiani, Alice Gerges-Geagea

Risultato della ricerca: Article

13 Citazioni (Scopus)

Abstract

Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
Lingua originaleEnglish
pagine (da-a)372-377
Numero di pagine6
RivistaBIOMEDICAL PAPERS OF THE THE FACULTY OF MEDICINE OF PALACKÝ UNIVERSITY, OLOMOUC CZECH REPUBLIC
Volume160
Stato di pubblicazionePublished - 2016

Fingerprint

Probiotics
Ulcerative Colitis
Mesalamine
Lactobacillus acidophilus
Bifidobacterium
Inflammatory Bowel Diseases
Oral Administration
Anti-Inflammatory Agents
Therapeutics
Dysbiosis
Weapons
Pharmaceutical Preparations
Clinical Studies
Adrenal Cortex Hormones

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cita questo

@article{5a332ad06e144b97914e0829a6928d30,
title = "The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study",
abstract = "Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.",
author = "{Lo Monte}, {Attilio Ignazio} and Francesco Carini and Giovanni Tomasello and Marcello Romeo and Giuseppe Damiano and {Marino Gammazza}, Antonella and Palumbo, {Vincenzo Davide} and Salvatore Buscemi and Provvidenza Damiani and {Lo Monte}, {Attilio Ignazio} and Abdo Jurjus and Francesco Carini and Gammazza, {Antonella Marino} and Provvidenza Damiani and Alice Gerges-Geagea",
year = "2016",
language = "English",
volume = "160",
pages = "372--377",
journal = "Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia",
issn = "1213-8118",
publisher = "Palacky University",

}

TY - JOUR

T1 - The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

AU - Lo Monte, Attilio Ignazio

AU - Carini, Francesco

AU - Tomasello, Giovanni

AU - Romeo, Marcello

AU - Damiano, Giuseppe

AU - Marino Gammazza, Antonella

AU - Palumbo, Vincenzo Davide

AU - Buscemi, Salvatore

AU - Damiani, Provvidenza

AU - Lo Monte, Attilio Ignazio

AU - Jurjus, Abdo

AU - Carini, Francesco

AU - Gammazza, Antonella Marino

AU - Damiani, Provvidenza

AU - Gerges-Geagea, Alice

PY - 2016

Y1 - 2016

N2 - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

AB - Aim. Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

UR - http://hdl.handle.net/10447/202597

UR - http://biomed.papers.upol.cz/doi/10.5507/bp.2016.044.pdf

M3 - Article

VL - 160

SP - 372

EP - 377

JO - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

JF - Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia

SN - 1213-8118

ER -